| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
|
Clin Ther
|
2015
|
1.73
|
|
2
|
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
|
J Clin Invest
|
2015
|
1.67
|
|
3
|
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
|
Trends Mol Med
|
2014
|
1.59
|
|
4
|
Immunotherapy in the treatment of non-small cell lung cancer.
|
Lung Cancer
|
2014
|
1.35
|
|
5
|
Intratumoral immunization: a new paradigm for cancer therapy.
|
Clin Cancer Res
|
2014
|
1.24
|
|
6
|
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
|
Oncoimmunology
|
2014
|
1.22
|
|
7
|
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
|
Cancer Immunol Res
|
2015
|
1.18
|
|
8
|
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
|
J Hematol Oncol
|
2016
|
1.12
|
|
9
|
Cancer immunotherapy in clinical practice -- the past, present, and future.
|
Chin J Cancer
|
2014
|
0.98
|
|
10
|
Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.
|
J Gastrointest Oncol
|
2015
|
0.89
|
|
11
|
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
|
World J Gastroenterol
|
2016
|
0.87
|
|
12
|
Immune checkpoint inhibitors: therapeutic advances in melanoma.
|
Ann Transl Med
|
2015
|
0.87
|
|
13
|
The tumor microenvironment in esophageal cancer.
|
Oncogene
|
2016
|
0.83
|
|
14
|
Novel therapeutic agents in the treatment of metastatic colorectal cancer.
|
World J Gastrointest Oncol
|
2016
|
0.83
|
|
15
|
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.
|
J Gastrointest Oncol
|
2016
|
0.83
|
|
16
|
A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.
|
Clin Transl Immunology
|
2016
|
0.82
|
|
17
|
Clinical Development of Immune Checkpoint Inhibitors.
|
Biomed Res Int
|
2015
|
0.82
|
|
18
|
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
|
J Clin Oncol
|
2017
|
0.82
|
|
19
|
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
|
Ther Adv Med Oncol
|
2016
|
0.81
|
|
20
|
Current and emerging therapies in unresectable and recurrent gastric cancer.
|
World J Gastroenterol
|
2016
|
0.81
|
|
21
|
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.
|
Onco Targets Ther
|
2016
|
0.81
|
|
22
|
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
|
Expert Rev Respir Med
|
2015
|
0.81
|
|
23
|
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
|
Gynecol Oncol Res Pract
|
2016
|
0.81
|
|
24
|
Major clinical research advances in gynecologic cancer in 2015.
|
J Gynecol Oncol
|
2016
|
0.81
|
|
25
|
The emerging role of immunotherapy in colorectal cancer.
|
Ann Transl Med
|
2016
|
0.80
|
|
26
|
PD-1 and PD-L1 antibodies for melanoma.
|
Hum Vaccin Immunother
|
2014
|
0.80
|
|
27
|
Immunotherapy for Gastroesophageal Cancer.
|
J Clin Med
|
2016
|
0.80
|
|
28
|
Emerging therapeutic targets in metastatic progression: A focus on breast cancer.
|
Pharmacol Ther
|
2016
|
0.79
|
|
29
|
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
|
Lancet Oncol
|
2017
|
0.78
|
|
30
|
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.
|
Transl Lung Cancer Res
|
2015
|
0.78
|
|
31
|
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.
|
J Immunol Res
|
2015
|
0.78
|
|
32
|
Antibody-based immunotherapy of solid cancers: progress and possibilities.
|
Immunotherapy
|
2015
|
0.77
|
|
33
|
Future perspectives in cancer immunotherapy.
|
Ann Transl Med
|
2016
|
0.77
|
|
34
|
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.
|
Ther Adv Med Oncol
|
2016
|
0.77
|
|
35
|
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
|
Lancet Oncol
|
2017
|
0.77
|
|
36
|
Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.
|
Cancers (Basel)
|
2016
|
0.75
|
|
37
|
Prime time for immune-checkpoint targeted therapy at ASCO 2015.
|
Oncoimmunology
|
2015
|
0.75
|
|
38
|
Opportunities in immunotherapy of ovarian cancer.
|
Ann Oncol
|
2016
|
0.75
|
|
39
|
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
|
J Transl Med
|
2016
|
0.75
|
|
40
|
Therapeutic targets and new directions for antibodies developed for ovarian cancer.
|
MAbs
|
2016
|
0.75
|